British Columbia Cancer Agency

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

18F-NaF PET Imaging for Bone Scintigraphy

Phase 3

Completed

Conditions: Bone Metastases From Breast or Prostate Cancer

Interventions: Procedure: NaF PET/CT Imaging
Procedure: 99mTc-medronate whole body bone scan with SPECT
Drug: 18F-Sodium Fluoride (NaF)

First Posted Date: 2013-08-29

Last Posted Date: 2019-04-25

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 286

Registration Number: NCT01930812

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦
Hamilton Health Sciences Corp., Hamilton, Ontario, Canada
🇨🇦
Centre hospitalier universitaire de Sherbrooke, Fleurimont, Quebec, Canada

and more 7 locations

Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer

Terminated

Conditions: Ovarian Cancer
Ovarian Neoplasms

First Posted Date: 2013-06-19

Last Posted Date: 2022-02-17

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 5

Registration Number: NCT01881451

Locations: 🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada

Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy

Not Applicable

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: Stereotactic Ablative Radiotherapy

First Posted Date: 2013-05-09

Last Posted Date: 2018-01-18

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 13

Registration Number: NCT01850316

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

Focal Therapy for Prostate Cancer - A Pilot Study of Focal Low Dose Rate Brachytherapy

Not Applicable

Conditions: Prostate Cancer

Interventions: Radiation: Low Dose Radiation Focal Brachytherapy

First Posted Date: 2013-04-12

Last Posted Date: 2017-07-13

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 10

Registration Number: NCT01830166

Locations: 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Phase 2

Withdrawn

Conditions: Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer

Interventions: Drug: Aromatase Inhibitor
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2013-03-20

Last Posted Date: 2013-12-20

Lead Sponsor: British Columbia Cancer Agency

Registration Number: NCT01814865

Locations: 🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦
The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
Segal Cancer Centre, Montreal, Quebec, Canada

and more 1 locations

Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies

Not Applicable

Completed

Conditions: Advanced Incurable Cancers

Interventions: Genetic: in depth genomic sequencing

First Posted Date: 2013-03-04

Last Posted Date: 2015-02-05

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 100

Registration Number: NCT01802905

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

HRV Biofeedback for Brain Tumour Survivors

Not Applicable

Suspended

Conditions: Anxiety
Sleep Impairment
Depression

Interventions: Behavioral: heart rate variability biofeedback

First Posted Date: 2013-01-21

Last Posted Date: 2015-05-06

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 15

Registration Number: NCT01772498

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

18F-FDG PET Imaging in Cardiac Sarcoidosis

Conditions: Cardiac Sarcoidosis

First Posted Date: 2013-01-09

Last Posted Date: 2022-02-04

Lead Sponsor: British Columbia Cancer Agency

Registration Number: NCT01764191

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos

Conditions: Mesothelioma
Lung Cancer

First Posted Date: 2012-11-01

Last Posted Date: 2012-11-01

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 200

Registration Number: NCT01719068

Locations: 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Phase 2

Conditions: Prostate Neoplasm

Interventions: Drug: Degarelix

First Posted Date: 2012-06-28

Last Posted Date: 2012-06-28

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 40

Registration Number: NCT01630967

Locations: 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy